Clinical Trials Browser

Phase NA × Not yet recruiting × Triple Negative Breast Neoplasms × Clear all

Triple Negative Breast Neoplasms

NCT07597642 2026-05-22

ONSET

Phase NA Not yet recruiting

55 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07513311 2026-04-09

RESTORE

Phase NA Not yet recruiting

75 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07478705 2026-03-17

EINSTEIN-TNBC

Phase NA Not yet recruiting

30 enrolled

Breast

Recurrence, Triple Negative Breast Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Phase NA Not yet recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06975644 2025-05-22

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Phase NA Not yet recruiting

55 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06497322 2024-07-11

Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment

Phase NA Not yet recruiting

60 enrolled

Breast

Breast Neoplasms, Motor Activity, Triple Negative Breast Neoplasms

NCT04225858 2020-01-13

ASICS

Phase NA Not yet recruiting

340 enrolled

Breast

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

OMICHIR

ONSET

RESTORE

EINSTEIN-TNBC

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment

ASICS